RADIOPHARM THERANOSTICS LIMITED - Announcements

8.82%

3.1¢

Market Cap $73.31M

Healthcare Biotechnology

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics... Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

RAD	Notice of Annual General Meeting/Proxy Form		18/10/23	500.73KB	Share
RAD	FDA green light for diagnostic Phase 1 pancreatic trial	PRICE SENSITIVE	17/10/23	178.96KB	Share
RAD	RAD receives approval for Phase 1 therapeutic study of NSCLC	PRICE SENSITIVE	09/10/23	134.02KB	Share
RAD	ESG Report		28/09/23	1.07MB	Share
RAD	Appendix 4G		28/09/23	332.93KB	Share
RAD	Corporate Governance Statement		28/09/23	888.09KB	Share
RAD	Annual Report to shareholders		28/09/23	1.82MB	Share
RAD	Appendix 4E and FY23 Financial Report	PRICE SENSITIVE	31/08/23	1.79MB	Share
RAD	TerThera Terbium-161 isotope supply agreement expanded	PRICE SENSITIVE	24/08/23	220.37KB	Share
RAD	Results of Meeting		18/08/23	121.18KB	Share
RAD	EGM Presentation		18/08/23	364.99KB	Share
RAD	Change of Director's Interest Notice IT		08/08/23	175.8KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	1.33MB	Share
RAD	Dr Sherin Al-Safadi appointed VP Medical & Corporate Affairs		24/07/23	132.41KB	Share
RAD	Notice of Extraordinary General Meeting/Proxy Form		20/07/23	383.69KB	Share
RAD	Notification of cessation of securities - RAD		30/06/23	21.85KB	Share
RAD	Notification regarding unquoted securities - RAD		30/06/23	25.26KB	Share
RAD	Pivalate educational webinar 14 June 2023		13/06/23	134.24KB	Share
RAD	FDA Pre-IND meeting supports an IND application for RAD 101	PRICE SENSITIVE	29/05/23	132.08KB	Share
RAD	RAD 301 receives FDA Orphan Drug Designation	PRICE SENSITIVE	09/05/23	227.82KB	Share
RAD	Application for quotation of securities - RAD		28/04/23	26.55KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	1.46MB	Share
RAD	Agreement with TerThera to supply Terbium-161 isotope	PRICE SENSITIVE	17/04/23	234.32KB	Share
RAD	Radiopharm Receives $1.56M R&D Tax Incentive		28/03/23	150.14KB	Share
RAD	Radiopharm to participate in Jefferies Radiopharma Summit		28/03/23	152KB	Share
RAD	RAD and GenesisCare to Develop Novel Radiopharmaceuticals		27/03/23	197.97KB	Share
RAD	RAD to present at virtual healthcare conference		17/03/23	130.43KB	Share
RAD	Notice Under Section 708A		06/03/23	124.03KB	Share
RAD	Application for quotation of securities - RAD		06/03/23	25.17KB	Share
RAD	Dr Ken Herrmann appointed to RAD Scientific Advisory Board		03/03/23	110.69KB	Share
RAD	Radiopharm to acquire Pharma15 Corporation	PRICE SENSITIVE	03/03/23	152.64KB	Share
RAD	Proposed issue of securities - RAD		03/03/23	24.82KB	Share
RAD	Appendix 4D and Half Year Report	PRICE SENSITIVE	28/02/23	1.56MB	Share
RAD	Notification regarding unquoted securities - RAD		14/02/23	25.06KB	Share
RAD	Radiopharm Theranostics initiates process for Nasdaq listing	PRICE SENSITIVE	14/02/23	209.93KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	2.19MB	Share
RAD	Dr. Rama Abu Shmeis appointed Senior VP, CMC		11/01/23	135.4KB	Share
RAD	Change in substantial holding - NT		06/01/23	751.89KB	Share
RAD	aVb6 Integrin (RAD301) IND approval for Phase 1 trial	PRICE SENSITIVE	30/12/22	140.65KB	Share
RAD	RAD201 HER2 nanobody demonstrates favourable tumor targeting		13/12/22	132.23KB	Share
RAD	Change in substantial holding - PH		09/12/22	245.73KB	Share
RAD	Change of Director's Interest Notice - PH		09/12/22	173.12KB	Share
RAD	Change of Director's Interest Notice - RC		09/12/22	173.08KB	Share
RAD	Change of Director's Interest Notice - IT		09/12/22	172.68KB	Share
RAD	Change of Director's Interest Notice - LA		09/12/22	171.86KB	Share
RAD	Change of Director's Interest Notice - HL		09/12/22	172.54KB	Share
RAD	Notification regarding unquoted securities - RAD		06/12/22	33.02KB	Share
RAD	Change of Director's Interest Notice - MB		02/12/22	192.92KB	Share
RAD	Change of Director's Interest Notice - IT		01/12/22	193.53KB	Share
RAD	Change of Director's Interest Notice - RC		29/11/22	171.93KB	Share
RAD	Change of Director's Interest Notice - PH		29/11/22	171.84KB	Share
RAD	Security Class Reinstatement to Quotation	PRICE SENSITIVE	28/11/22	86.74KB	Share
RAD	Notice Under Section 708A		25/11/22	123.4KB	Share
RAD	Application for quotation of securities - RAD		25/11/22	25.54KB	Share
RAD	Top Holders Report RADO Options		25/11/22	72.25KB	Share
RAD	Appendix 2A		25/11/22	377.1KB	Share
RAD	Additional data released from brain metastases imaging trial		23/11/22	898.91KB	Share
RAD	Successful completion of Retail Entitlement Offer		22/11/22	137.96KB	Share
RAD	RAD agreement with ANSTO to supply key isotope lutetium-177		22/11/22	156.71KB	Share
RAD	Security Class Suspension from Quotation RADO	PRICE SENSITIVE	21/11/22	88.79KB	Share
RAD	Application for quotation of securities - RAD		18/11/22	24.4KB	Share
RAD	Results of Annual General Meeting		16/11/22	564.43KB	Share
RAD	AGM Presentation		16/11/22	1.13MB	Share
RAD	AGM ATTENDANCE		08/11/22	145.63KB	Share
RAD	Notification of Release of Shares from Escrow		08/11/22	145.48KB	Share
RAD	Update - Proposed issue of securities		08/11/22	697.49KB	Share
RAD	Entitlement Offer - Extension of Retail Offer	PRICE SENSITIVE	08/11/22	132.56KB	Share
RAD	Change in substantial holding - PH		31/10/22	232.94KB	Share
RAD	Change of Director's Interest Notice - PH		31/10/22	183.27KB	Share
RAD	Change of Director's Interest Notice - RC		31/10/22	202.04KB	Share
RAD	Notice Under Section 708A		27/10/22	173.9KB	Share
RAD	Application for quotation of securities - RAD		26/10/22	25.47KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/10/22	2.37MB	Share
RAD	RAD agreement with NorthStar for supply of Actinium-225	PRICE SENSITIVE	26/10/22	165.97KB	Share
RAD	Entitlement Offer - Letter to Ineligible Shareholders		25/10/22	583.03KB	Share
RAD	Entitlement Offer - Letter to Option Holders		25/10/22	572.05KB	Share
RAD	Entitlement Offer - Letter to Eligible Retail Shareholders		25/10/22	588.4KB	Share
RAD	Appendix 2A		25/10/22	377.62KB	Share
RAD	Update - Proposed issue of securities		20/10/22	696.9KB	Share
RAD	Reinstatement to Quotation	PRICE SENSITIVE	20/10/22	85.7KB	Share
RAD	Supplementary Prospectus		20/10/22	178.08KB	Share
RAD	Successful Completion of Institutional Entitlement Offer	PRICE SENSITIVE	20/10/22	264.11KB	Share
RAD	Update - Proposed issue of securities - RAD		19/10/22	35.15KB	Share
RAD	Entitlement Offer - Presentation		19/10/22	2.01MB	Share
RAD	Entitlement Offer to raise up to $10 million	PRICE SENSITIVE	19/10/22	228.35KB	Share
RAD	Prospectus	PRICE SENSITIVE	19/10/22	1.32MB	Share
RAD	Proposed issue of securities - RAD		19/10/22	35.42KB	Share
RAD	Investor webinar - Pivalate positive Phase 2 data		18/10/22	110.34KB	Share
RAD	Presentation - Pivalate achieves positive Phase 2 data	PRICE SENSITIVE	18/10/22	516.24KB	Share
RAD	Pivalate achieves positive Phase 2 data in brain mets trial	PRICE SENSITIVE	18/10/22	156.41KB	Share
RAD	Suspension from Official Quotation	PRICE SENSITIVE	17/10/22	124.19KB	Share
RAD	Notice of Annual General Meeting/Proxy Form		17/10/22	1.16MB	Share
RAD	Trading Halt	PRICE SENSITIVE	13/10/22	124.06KB	Share
RAD	Additional Information - LR4.10.19		05/10/22	143.25KB	Share
RAD	NATURE releases encouraging data on role of DUNP19 receptors		04/10/22	174.06KB	Share
RAD	Corporate Governance Statement		30/09/22	185.02KB	Share
RAD	ESG Report		30/09/22	670.45KB	Share
RAD	Appendix 4G		30/09/22	254.07KB	Share
RAD	Corporate Governance Statement		30/09/22	185.31KB	Share
RAD	Annual Report to shareholders		30/09/22	1.82MB	Share

RAD Notice of Annual General Meeting/Proxy Form
18/10/23		500.73KB	Share
RAD FDA green light for diagnostic Phase 1 pancreatic trial
17/10/23	PRICE SENSITIVE	178.96KB	Share
RAD RAD receives approval for Phase 1 therapeutic study of NSCLC
09/10/23	PRICE SENSITIVE	134.02KB	Share
RAD ESG Report
28/09/23		1.07MB	Share
RAD Appendix 4G
28/09/23		332.93KB	Share
RAD Corporate Governance Statement
28/09/23		888.09KB	Share
RAD Annual Report to shareholders
28/09/23		1.82MB	Share
RAD Appendix 4E and FY23 Financial Report
31/08/23	PRICE SENSITIVE	1.79MB	Share
RAD TerThera Terbium-161 isotope supply agreement expanded
24/08/23	PRICE SENSITIVE	220.37KB	Share
RAD Results of Meeting
18/08/23		121.18KB	Share
RAD EGM Presentation
18/08/23		364.99KB	Share
RAD Change of Director's Interest Notice IT
08/08/23		175.8KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	1.33MB	Share
RAD Dr Sherin Al-Safadi appointed VP Medical & Corporate Affairs
24/07/23		132.41KB	Share
RAD Notice of Extraordinary General Meeting/Proxy Form
20/07/23		383.69KB	Share
RAD Notification of cessation of securities - RAD
30/06/23		21.85KB	Share
RAD Notification regarding unquoted securities - RAD
30/06/23		25.26KB	Share
RAD Pivalate educational webinar 14 June 2023
13/06/23		134.24KB	Share
RAD FDA Pre-IND meeting supports an IND application for RAD 101
29/05/23	PRICE SENSITIVE	132.08KB	Share
RAD RAD 301 receives FDA Orphan Drug Designation
09/05/23	PRICE SENSITIVE	227.82KB	Share
RAD Application for quotation of securities - RAD
28/04/23		26.55KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	1.46MB	Share
RAD Agreement with TerThera to supply Terbium-161 isotope
17/04/23	PRICE SENSITIVE	234.32KB	Share
RAD Radiopharm Receives $1.56M R&D Tax Incentive
28/03/23		150.14KB	Share
RAD Radiopharm to participate in Jefferies Radiopharma Summit
28/03/23		152KB	Share
RAD RAD and GenesisCare to Develop Novel Radiopharmaceuticals
27/03/23		197.97KB	Share
RAD RAD to present at virtual healthcare conference
17/03/23		130.43KB	Share
RAD Notice Under Section 708A
06/03/23		124.03KB	Share
RAD Application for quotation of securities - RAD
06/03/23		25.17KB	Share
RAD Dr Ken Herrmann appointed to RAD Scientific Advisory Board
03/03/23		110.69KB	Share
RAD Radiopharm to acquire Pharma15 Corporation
03/03/23	PRICE SENSITIVE	152.64KB	Share
RAD Proposed issue of securities - RAD
03/03/23		24.82KB	Share
RAD Appendix 4D and Half Year Report
28/02/23	PRICE SENSITIVE	1.56MB	Share
RAD Notification regarding unquoted securities - RAD
14/02/23		25.06KB	Share
RAD Radiopharm Theranostics initiates process for Nasdaq listing
14/02/23	PRICE SENSITIVE	209.93KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	2.19MB	Share
RAD Dr. Rama Abu Shmeis appointed Senior VP, CMC
11/01/23		135.4KB	Share
RAD Change in substantial holding - NT
06/01/23		751.89KB	Share
RAD aVb6 Integrin (RAD301) IND approval for Phase 1 trial
30/12/22	PRICE SENSITIVE	140.65KB	Share
RAD RAD201 HER2 nanobody demonstrates favourable tumor targeting
13/12/22		132.23KB	Share
RAD Change in substantial holding - PH
09/12/22		245.73KB	Share
RAD Change of Director's Interest Notice - PH
09/12/22		173.12KB	Share
RAD Change of Director's Interest Notice - RC
09/12/22		173.08KB	Share
RAD Change of Director's Interest Notice - IT
09/12/22		172.68KB	Share
RAD Change of Director's Interest Notice - LA
09/12/22		171.86KB	Share
RAD Change of Director's Interest Notice - HL
09/12/22		172.54KB	Share
RAD Notification regarding unquoted securities - RAD
06/12/22		33.02KB	Share
RAD Change of Director's Interest Notice - MB
02/12/22		192.92KB	Share
RAD Change of Director's Interest Notice - IT
01/12/22		193.53KB	Share
RAD Change of Director's Interest Notice - RC
29/11/22		171.93KB	Share
RAD Change of Director's Interest Notice - PH
29/11/22		171.84KB	Share
RAD Security Class Reinstatement to Quotation
28/11/22	PRICE SENSITIVE	86.74KB	Share
RAD Notice Under Section 708A
25/11/22		123.4KB	Share
RAD Application for quotation of securities - RAD
25/11/22		25.54KB	Share
RAD Top Holders Report RADO Options
25/11/22		72.25KB	Share
RAD Appendix 2A
25/11/22		377.1KB	Share
RAD Additional data released from brain metastases imaging trial
23/11/22		898.91KB	Share
RAD Successful completion of Retail Entitlement Offer
22/11/22		137.96KB	Share
RAD RAD agreement with ANSTO to supply key isotope lutetium-177
22/11/22		156.71KB	Share
RAD Security Class Suspension from Quotation RADO
21/11/22	PRICE SENSITIVE	88.79KB	Share
RAD Application for quotation of securities - RAD
18/11/22		24.4KB	Share
RAD Results of Annual General Meeting
16/11/22		564.43KB	Share
RAD AGM Presentation
16/11/22		1.13MB	Share
RAD AGM ATTENDANCE
08/11/22		145.63KB	Share
RAD Notification of Release of Shares from Escrow
08/11/22		145.48KB	Share
RAD Update - Proposed issue of securities
08/11/22		697.49KB	Share
RAD Entitlement Offer - Extension of Retail Offer
08/11/22	PRICE SENSITIVE	132.56KB	Share
RAD Change in substantial holding - PH
31/10/22		232.94KB	Share
RAD Change of Director's Interest Notice - PH
31/10/22		183.27KB	Share
RAD Change of Director's Interest Notice - RC
31/10/22		202.04KB	Share
RAD Notice Under Section 708A
27/10/22		173.9KB	Share
RAD Application for quotation of securities - RAD
26/10/22		25.47KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
26/10/22	PRICE SENSITIVE	2.37MB	Share
RAD RAD agreement with NorthStar for supply of Actinium-225
26/10/22	PRICE SENSITIVE	165.97KB	Share
RAD Entitlement Offer - Letter to Ineligible Shareholders
25/10/22		583.03KB	Share
RAD Entitlement Offer - Letter to Option Holders
25/10/22		572.05KB	Share
RAD Entitlement Offer - Letter to Eligible Retail Shareholders
25/10/22		588.4KB	Share
RAD Appendix 2A
25/10/22		377.62KB	Share
RAD Update - Proposed issue of securities
20/10/22		696.9KB	Share
RAD Reinstatement to Quotation
20/10/22	PRICE SENSITIVE	85.7KB	Share
RAD Supplementary Prospectus
20/10/22		178.08KB	Share
RAD Successful Completion of Institutional Entitlement Offer
20/10/22	PRICE SENSITIVE	264.11KB	Share
RAD Update - Proposed issue of securities - RAD
19/10/22		35.15KB	Share
RAD Entitlement Offer - Presentation
19/10/22		2.01MB	Share
RAD Entitlement Offer to raise up to $10 million
19/10/22	PRICE SENSITIVE	228.35KB	Share
RAD Prospectus
19/10/22	PRICE SENSITIVE	1.32MB	Share
RAD Proposed issue of securities - RAD
19/10/22		35.42KB	Share
RAD Investor webinar - Pivalate positive Phase 2 data
18/10/22		110.34KB	Share
RAD Presentation - Pivalate achieves positive Phase 2 data
18/10/22	PRICE SENSITIVE	516.24KB	Share
RAD Pivalate achieves positive Phase 2 data in brain mets trial
18/10/22	PRICE SENSITIVE	156.41KB	Share
RAD Suspension from Official Quotation
17/10/22	PRICE SENSITIVE	124.19KB	Share
RAD Notice of Annual General Meeting/Proxy Form
17/10/22		1.16MB	Share
RAD Trading Halt
13/10/22	PRICE SENSITIVE	124.06KB	Share
RAD Additional Information - LR4.10.19
05/10/22		143.25KB	Share
RAD NATURE releases encouraging data on role of DUNP19 receptors
04/10/22		174.06KB	Share
RAD Corporate Governance Statement
30/09/22		185.02KB	Share
RAD ESG Report
30/09/22		670.45KB	Share
RAD Appendix 4G
30/09/22		254.07KB	Share
RAD Corporate Governance Statement
30/09/22		185.31KB	Share
RAD Annual Report to shareholders
30/09/22		1.82MB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.1¢		Change -0.003(8.82%)		Mkt cap ! $73.31M

Open	High	Low	Value	Volume
3.4¢	3.4¢	3.1¢	$58.95K	1.821M

Buyers (Bids)

No.	Vol.	Price($)
4	783888	3.1¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	870662	1

View Market Depth

No.	Vol.	Price($)
3	683888	0.031
3	1230000	0.030
6	505133	0.029
3	649718	0.028
5	1761111	0.027

Price($)	Vol.	No.
0.032	870662	1
0.033	325000	1
0.034	1090328	2
0.035	2373494	10
0.036	1165378	3

Last trade - 16.10pm 19/09/2025 (20 minute delay)

RAD (ASX) Chart

RADIOPHARM THERANOSTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available